ABOS logo

Acumen Pharmaceuticals, Inc. Common Stock


ABOS: Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believe to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.


Show ABOS Financials

Consumer Interest
SEC Filings

Recent trades of ABOS by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by ABOS's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 Apr. 26, 2016
  • Patent Title: Antibodies, kit and method for detecting amyloid beta oligomers Apr. 12, 2016
  • Patent Title: Addl receptor polypeptides, polynucleotides and host cells for recombinant production Dec. 22, 2015
  • Patent Title: Antibodies, kit and method for detecting amyloid beta oligomers Nov. 03, 2015
  • Patent Title: Methods of modifying amyloid β oligomers using non-peptidic compounds Apr. 14, 2015
  • Patent Title: Methods of restoring cognitive ability using non-peptidic compounds Feb. 24, 2015
  • Patent Title: Compositions and methods for the enhancement of soluble amyloid beta oligomer (addl) uptake and clearance Jun. 21, 2011
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of ABOS in WallStreetBets Daily Discussion


Recent insights relating to ABOS

CNBC Recommendations

Recent picks made for ABOS stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ABOS

Corporate Flights

Flights by private jets registered to ABOS